ODP444 The Effect of Glucocorticoid Therapy on Cardio-Metabolic Risk in Patients with Multiple Sclerosis

Abstract

Abstract Multiple sclerosis (MS) often requires usage of glucocorticoids (GC). Excess of GC may affect muscles, which increases mortality. This study evaluates the effect of GC therapy on muscles and cardiovascular disease (CVD) risk factors in patients with MS. Methods 45 patients (55.5% women), 37.8 (20-45) years, were examined. 51% of patients received GC (methylprednisolone 3000-5000 mg, 3-5 days). MS duration was 5.9±1.2 years, the assessment by EDSS - 3.3±1.2. Muscle tissue was assessed by bioimpedance analysis, a chair-rising test, dynamometry. Glucose and lipid metabolism, blood pressure (BP), body mass index (BMI), waist circumference (WC),physical activity were evaluated. Statistical analysis was carried out using "Statistica 10. 0". Normal distribution was tested by the Shapiro–Wilks test, p>0. 05. А Mann-Whitney U-test, a t-test,χ2 test were used,p<0. 05. Results Patients with GC had significantly higher BMI (28.56±5. 02 vs 22.87±3.49 kg/m2), WC (98 (66-123) vs 79.9±5.27cm), lower muscle mass (36.4 (35-38) vs 40.75±2. 02 kg). A negative correlation between GC dose and a grip strength of the dominant hand among men was noted (r=-0.88, p<0. 0001). A normal WС was identified in 52% of patients. Comparing with others received GC, they had a lower level of low-density lipoproteins (1.35±0.39 vs 1.39(1-3,32) mmol/l), systolic BP (132.3±15.7 vs 141 (100-165)) and better handgrip strength (40 (25-47) vs 27±7.3 daN). Conclusions The negative effect of GC on cardiometabolic parameters in all patients with MS and muscle strength in men was confirmed. Metabolic healthier patients probably have a resistance to GC side effects, which may be determined genetically. It is promising for finding protective factors against GC. Presentation: No date and time listed